For the development of treatments against:
Targeting the root cause
Plasar is at the forefront of fundamental research into primate-specific RNA genes, offering an innovative approach to medical therapies. We engage human genes using the mechanism of double-stranded RNA (RNAi), specifically targeting primate-specific RNA genes.
Our method opens new avenues for treating diseases associated with long non-coding RNAs, which were resistant to conventional treatment methods prior to our intervention.
A distinctive feature of Plasar is our ability to identify and treat diseases caused by primate-unique genes. We are pushing the boundaries of traditional medicine, providing groundbreaking solutions in RNA therapy. Before our work, the use of primate-specific genes as therapeutic targets was unexplored, positioning Plasar as a leader in the development of this promising field.
The founder, visionary leader and the supervisor of the team is Professor Leonard Lipovich.
A B.A. cum laude graduate of Cornell University, he earned his Ph.D. in Genome Sciences at the University of Washington — Seattle, and after this rigorous training at two of America’s best universities, he completed his postdoctoral research at the Genome Institute of Singapore. Subsequently, Dr. Lipovich joined the School of Medicine at Wayne State University in Detroit, Michigan, U.S., where he was an assistant professor, associate professor, and full professor (tenured). He remains with Wayne State as an Adjunct Professor of Molecular Medicine and Genetics.
To date, Dr. Lipovich (h-index: 45) has published 87 peer-reviewed papers, delivered over 50 talks, chaired prestigious international conferences including the first-ever scientific meeting of The Royal Society devoted to lncRNA and the first-ever Keystone Symposium devoted to the topic. He has organized and chaired numerous sessions at other key conferences, and has been a co-chair of the U.S. National Science Foundation-funded Annual LncRNA Workshop at the IEEE-BIBM Conference for the past five years. Dr. Lipovich is a 2014–2019 laureate of the prestigious U.S. National Institutes of Health (NIH) Director’s New Innovator Award. His total research funding in the U.S. surpassed $6,000,000.
Exclusive access to world-class laboratories and primates for testing allows us to effectively test our developments in practice, confirming the efficacy of our drugs under real-world conditions.
Exclusive access to world-class laboratories and primates for testing allows us to effectively test our developments in practice, confirming the efficacy of our drugs under real-world conditions.
Exclusive access to world-class laboratories and primates for testing allows us to effectively test our developments in practice, confirming the efficacy of our drugs under real-world conditions.
Exclusive access to world-class laboratories and primates for testing allows us to effectively test our developments in practice, confirming the efficacy of our drugs under real-world conditions.